Accelerated approval requirements for lurbinectedin

Lancet Oncol. 2022 May;23(5):e206. doi: 10.1016/S1470-2045(22)00193-0.
No abstract available

Publication types

  • Letter

MeSH terms

  • Carbolines* / adverse effects
  • Heterocyclic Compounds, 4 or More Rings* / adverse effects
  • Humans

Substances

  • Carbolines
  • Heterocyclic Compounds, 4 or More Rings
  • PM 01183